Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.

None © Shutterstock

While TLRs are receptors that detect bacteria, funghi and viruses, they are also implicated in the processes that perpetuate auto-immune diseases such as rheumatoid arthritis. In patients that failed to respond adequately to the standard treatment, there was a measurable difference in the receptors prior to treatment compared to those of patients that responded well. There was also a different profile of TLRs in the joints of rheumatoid arthritis patients compared to osteoarthritis patients. Other tissues from different stages of arthritis also showed different TLR profiles, allowing researchers to map the changes throughout the course of disease. 

Dr Clanchy, the corresponding and lead author says: "The patients that fail to respond to anti-TNF treatments have other treatment options but it would be better if we could match them to the best treatment from the beginning. Stratifying patients to the most appropriate treatment is a major challenge for rheumatoid arthritis, and finding biomarkers that sort patients to the best treatment would be helpful.”

Professor Williams continues:" This study builds on existing knowledge regarding the involvement of TLRs in rheumatoid arthritis and suggests that they could act as biomarkers to enable patient stratification."

The research was funded by in part by the MASTERSWITCH consortium (Mechanisms to Attack Steering Effectors of Rheumatoid Syndromes with Innovated Therapy Choices) as part of the EU 7th Framework Programme, an MRC-DPFS grant and a BBSRC CASE studentship.

Similar stories

The new Botnar strategy is announced

After a year as the Director of the Botnar Institute for Musculoskeletal Sciences, Professor Jonathan Rees announces a new structure and strategy that will further enhance research and treatment of bone, joint and musculoskeletal conditions.

New global health grant to improve outcomes for patients with hip fracture

Hip fracture patients in Low- and Middle-Income Countries (LMIC) in Asia are set to benefit from a new study that aims to bring best practice programmes to improve quality of life for patients and reduce healthcare costs.

NDORMS welcomes great-granddaughter of former Head of Department

Julia Strubell, great-granddaughter of Professor Josep Trueta, visited NDORMS to find out about his time here and to share her own work with staff and students.

Botnar researchers awarded Fellowships

Arani Vivekanantham has been awarded an NIHR Doctoral Fellowship and a Versus Arthritis Clinical Research Fellowship, and Rachel Kuo was awarded an NIHR Doctoral Research Fellowship.

Better diagnosis and treatment of autoimmune diseases moves a step closer

A study published in Nature outlines a way to find the crucial peptides (protein fragments) that drive autoimmunity, as well as the immune cells that respond to them.

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.